CNS Pharmaceuticals Stock Price, News & Analysis

CNS Pharmaceuticals has initiated dosing for its first patient in France as part of a global trial for Berubicin, targeting recurrent glioblastoma multiforme (GBM).

The ongoing study aims to evaluate the drug's safety and efficacy, with a planned interim analysis after 30-50% of participants complete six months in the trial. A total of 68 trial sites across the U.S. and Europe have been established.

Berubicin, the first anthracycline to cross the blood-brain barrier, has received Fast Track and Orphan Drug Designation from the FDA.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced participation in the American Brain Tumor Association's Breakthrough for Brain Tumors® 5K Run on November 5, 2022, in Los Angeles, CA. CEO John Climaco emphasized the urgent need for effective glioblastoma treatment options, stating, "Supporting these patients is not just a priority; it is why we do what we do." The event aims to raise funds for brain tumor research and patient care. CNS Pharmaceuticals is developing innovative cancer treatments, including Berubicin, which crosses the blood-brain barrier, and WP1244, a potent drug candidate for various cancers.

CNS Pharmaceuticals (NASDAQ: CNSP) has announced the activation of its first clinical trial sites in Europe for a pivotal global trial of Berubicin, a treatment for recurrent glioblastoma multiforme (GBM). This action supports the ongoing evaluation of Berubicin's efficacy and safety against the standard care, Lomustine. The FDA has granted Fast Track and Orphan Drug Designations for Berubicin, accelerating its development process. CEO John Climaco emphasized the commitment to advancing this clinical program and the urgency of addressing the unmet needs in GBM.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) has initiated its first clinical trial sites in Europe, specifically in France and Spain, for the global study evaluating Berubicin against recurrent glioblastoma multiforme (GBM), a severe brain cancer. Currently, 26 of 59 planned sites are open across various countries including the U.S. and Italy. This potentially pivotal trial aims to assess Berubicin's efficacy compared to Lomustine, with Overall Survival as the primary endpoint. The FDA has granted Berubicin Fast Track and Orphan Drug Designation, facilitating expedited development.

CNS Pharmaceuticals (NASDAQ: CNSP) will host a live moderated video webcast on September 28, 2022, at 1:00 PM ET to discuss its pivotal global study of Berubicin for treating glioblastoma multiforme (GBM). This adaptive, multicenter trial aims to assess the drug’s efficacy and safety in patients with recurrent GBM following standard therapy failure, focusing on overall survival as the primary endpoint. An interim analysis will evaluate safety and efficacy after 30-50% of patients complete the study. The event will allow audience questions.

CNS Pharmaceuticals (NASDAQ: CNSP) announced that CEO John Climaco will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York from September 12-14, 2022. A video webcast of the presentation will be available on-demand starting September 12 at 7:00 AM ET and archived for 90 days. CNS Pharmaceuticals focuses on developing innovative cancer treatments, including its lead drug Berubicin, which targets brain cancers. The company will also participate in virtual one-on-one meetings with qualified investors during the conference.

CNS Pharmaceuticals reported its Q2 2022 financial results, posting a net loss of approximately $3.6 million, an improvement from $3.8 million in Q2 2021. The company continues to execute on its clinical operations for Berubicin, a drug being evaluated in a pivotal global trial for Glioblastoma Multiforme (GBM). Currently, 23 out of 54 clinical trial sites are operational across the U.S. and Europe, with European enrollment expected soon. The company maintains a cash position of $9.0 million, expected to fund operations into 2023.

CNS Pharmaceuticals (NASDAQ: CNSP) is urging shareholders to vote in favor of two proposals at the upcoming Annual Shareholder Meeting on July 27, 2022. The proposals seek authorization to increase the number of shares available for issuance and allow the Board to conduct a reverse stock split at a ratio between 1-for-2 and 1-for-30. CEO John Climaco emphasized the necessity of these measures to secure financing and maintain the NASDAQ listing amidst challenging market conditions, while stressing that such actions will only be undertaken if truly needed.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced FDA approval for a protocol amendment to its global trial on Berubicin, targeting recurrent glioblastoma multiforme (GBM). The trial has expanded patient eligibility to those who have undergone multiple first-line therapies. With 19 clinical sites currently active and an additional 42 set to open in Europe and the U.S., the company aims to enhance patient access. A non-binding futility analysis will occur after 30-50% of subjects complete six months, without pausing enrollment. Berubicin, noted for crossing the blood-brain barrier, demonstrates potential in treating aggressive brain cancer.